1. Home
  2. EVC vs CLLS Comparison

EVC vs CLLS Comparison

Compare EVC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

HOLD

Current Price

$3.85

Market Cap

335.0M

Sector

Industrials

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.02

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVC
CLLS
Founded
1996
1999
Country
United States
France
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
335.0M
384.3M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
EVC
CLLS
Price
$3.85
$4.02
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.33
AVG Volume (30 Days)
270.6K
32.7K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
5.33%
N/A
EPS Growth
47.59
N/A
EPS
N/A
N/A
Revenue
$536,034,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.76
$1.33
52 Week High
$3.74
$5.48

Technical Indicators

Market Signals
Indicator
EVC
CLLS
Relative Strength Index (RSI) 78.71 57.62
Support Level $2.87 $3.93
Resistance Level N/A $4.48
Average True Range (ATR) 0.12 0.20
MACD 0.05 0.01
Stochastic Oscillator 88.69 57.13

Price Performance

Historical Comparison
EVC
CLLS

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: